Bardoxolone Methyl for Alport Syndrome: Opportunities and Challenges

Clin J Am Soc Nephrol. 2022 Dec;17(12):1713-1715. doi: 10.2215/CJN.12491022. Epub 2022 Nov 21.

Authors

Catherine Quinlan^{1

2

3

4}, Kushani Jayasinghe^{2

4

5

6}

Affiliations

¹ Department of Nephrology, Royal Children's Hospital, Melbourne, Australia.
² Kidney Regeneration, Murdoch Children's Research Institute, Melbourne, Australia.
³ Department of Paediatrics, University of Melbourne, Melbourne, Australia.
⁴ Melbourne Genomics Health Alliance, Melbourne, Australia.
⁵ Department of Nephrology, Monash Health, Melbourne, Australia.
⁶ Department of Medicine, Monash University, Melbourne, Australia.

No abstract available

Keywords: Alport syndrome; bardoxolone; clinical trial; genetic kidney disease; hematuria; proteinuria; therapy.

Publication types

Editorial
Comment

MeSH terms

Collagen Type IV
Hematuria
Humans
Kidney
Nephritis, Hereditary* / drug therapy
Oleanolic Acid*

Substances

bardoxolone methyl
Oleanolic Acid
Collagen Type IV